+65 63464191 info@healthytimes.com.sg
Health Magazine Singapore l Singapore Health Magazine l Healthy Times Magazine
  • Home
  • Health
  • Fitness
  • Beauty
  • Food & Nutrition
  • Green Living
  • Kids & Women
  • Disease and Prevention
  • Well Being
  • Events
  • Bahasa
Select Page

1664 ANNOUNCES FIRST-EVER ASIA-WIDE ARTIST COLLABORATION WITH FRENCH ARTIST CAMILLE WALALA

by | PRNewswire Asia

A Joyful, Design-led Partnership to Celebrate the Festive Season HONG KONG, Oct. 20, 2025 /PRNewswire/ — This festive season, 1664 is excited to announce its first-ever festive artist collaboration across Hong Kong, mainland China, Singapore, Malaysia, and...

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

by | PRNewswire Asia

SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ — Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class...

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

by | PRNewswire Asia

–          The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule...

Significant OS Benefit with Cadonilimab in First-Line Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented at ESMO 2025

by | PRNewswire Asia

HONG KONG, Oct. 19, 2025 /PRNewswire/ — On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) .  COMPASSION-15 is a Phase...

HARMONi-6 Data: mPFS 11.14 Months (HR=0.6, P<0.0001) Simultaneously Released at ESMO and in The Lancet

by | PRNewswire Asia

Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001. The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival...

International Technology Night: OMODA&JAECOO Leverage Power and Smart Mobility to Lead a New Wave of User Co-Creation

by | PRNewswire Asia

KUALA LUMPUR, Malaysia and WUHU, China, Oct. 19, 2025 /PRNewswire/ — In October 2025, the OMODA&JAECOO International User Summit was grandly held to worldwide attention, with the International Technology Night becoming the highlight of the event. During...
« Older Entries
Next Entries »
  • Beauty
  • Disease and Prevention
  • Events
  • Fitness
  • Food and Nutrition
  • Green Living
  • Health
  • Kids and Women
  • News
  • Well Being

PRNewswire Asia

Sitemap

Links

editor@healthytimes.com.sg

editor@healthytimes.com.sg (Press Release)

Phone:+65 63464191

  • Facebook
© Copyright healthytimes.com.sg